Glycogen-Rich Clear Cell Carcinoma: A Rare Variant of Breast Carcinoma of Uncertain Significance

2017 ◽  
Vol 26 (6) ◽  
pp. 530-531
Author(s):  
Naomi E. Akagi ◽  
Julie M. Jorns
Pathology ◽  
2019 ◽  
Vol 51 (7) ◽  
pp. 750-752
Author(s):  
Min-Shu Hsieh ◽  
Kuen-Yuan Chen ◽  
Yi-Hsuan Lee ◽  
Hsuan Wang

2003 ◽  
Vol 13 (1) ◽  
pp. 28-31 ◽  
Author(s):  
H. Iwamoto ◽  
H. Fukasawa ◽  
T. Honda ◽  
S. Hirata ◽  
K. Hoshi

HER-2 /neu is a 185-kDa glycoprotein and a transmembrane receptor with tyrosine kinase activity. Its overexpression is observed in 25–30% of primary breast carcinomas and is associated with a poor clinical prognosis. Recently, the U.S. Food and Drug Administration and the Japanese Ministry of Health, Welfare, and Labor approved the use of trastuzumab (Herceptin, Genentech, South San Francisco, CA) for the treatment of patients with metastatic breast carcinomas overexpressing HER-2 /neu. Results of clinical trials with Herceptin suggest that it may prolong the survival of patients with advanced metastatic breast carcinoma. Relatively little is known concerning the relationship between HER-2 /neu status and ovarian clear cell carcinoma. If HER-2 /neu overexpression status were demonstrable in ovarian clear cell carcinoma and a clinical correlation between overexpression and prognosis could be established, a rationale for clinical use of Herceptin for this tumor could be established. Our aim was to evaluate HER-2 /neu status in ovarian clear cell carcinomas. Fifteen ovarian clear cell carcinoma cases were immunostained for HER-2 /neu using HercepTest (DAKO, Glostrup, Denmark). Overexpression of HER-2 /neu was detected in only one case. Unlike in breast carcinoma, HER-2 /neu overexpression appeared to be uncommon in ovarian clear cell carcinomas. Herceptin may thus target only a small proportion of ovarian clear cell carcinomas and be of limited clinical value for treatment of this carcinoma.


2019 ◽  
Vol 6 (2) ◽  
pp. 146-149
Author(s):  
Finot Finot ◽  
Dik Puspasari ◽  
Siti Amarwati

Background: Glycogen rich clear cell carcinoma is a rare neoplasm of the breast, with the incidence of 1.4-3% of all breast cancers. The tumour has distinct morphology, different from that of common breast cancers. Glycogen rich clear cell carcinomas are members of a heterogeneous group of neoplasms, including signet-ring, secretory and lipid-rich carcinomas of the breast. In general, clear cell breast carcinoma tends to follow an aggressive clinical course. Case report: To present a case of a 47 years old woman suffering from breast mass in the upper outer quadrant of her right breast. On macroscopic examination, the biopsy tumor sized 2x1.5x0.5 cm and solid with brown and white. Discussion: Microscopic examination showed breast tissue composed of tumor cells arranged in nets, trabeculae and singly dispersed. Tumor cells are moderately pleomorphic, have sharply defined border and polygonal contours. Cytoplasm is clear in more than 90% of cells and finely granular in few cells. Nuclei are hyperchromatic with clumped chromatin and prominent nucleoli. Occasional mitosis is also observed. Special stain (PAS Staining): Intracytoplasmic PAS positivity in tumor cells are variable. Immunohistochemistry ER (+) positive >20-50%, PR (+) positive <20%, HER2 (-) negative. The patient was diagnosed with glycogen rich clear cell carcinoma. Conclusion: Glycogen rich clear cell carcinoma of the breast is rare. Its clinical feature is rather aggressive and varies depending on special characteristics such as low grade. Keywords: Glycogen rich clear cell carcinoma, breast carcinoma, PAS staining   Latar belakang: Glycogen rich clear cell carcinoma adalah kanker payudara yang jarang, dengan insidensi 1.4-3% dari semua kanker payudara. Tumor memiliki morfologi yang berbeda dari kanker payudara pada umunya. Glycogen rich clear cell carcinoma merupakan neoplasma heterogen yang termasuk karsinoma payudara signet-ring, sekretori dan kaya lipid. Secara umum, carcinoma ini cenderung mengikuti perjalanan klinis yang agresif. Tujuan: Laporan Kasus: Dilakukan pemeriksaan makroskopis jaringan tumor dari seorang perempuan berusia 47 tahun dengan massa payudara kanan di kuadran luar atas. Tumor biopsi berukuran 2x1.5x0.5 cm, komposisi padat, berwarna coklat dan putih. Dilakukan pemeriksaan histopatologi, imunohistokimia dan histokimia pewarnaan khusus PAS (Periodic Acid Schiff). Pembahasan: Pemeriksaan mikroskopis menunjukkan jaringan payudara dengan sel-sel tumor yang tersusun dalam jaring, trabekula dan tersebar tunggal. Sel-sel tumor cukup pleomorfik, hiperkromatik, kromatin kasar dan nucleoli prominent, mitosis dapat ditemukan, sitoplasma jernih lebih dari 90% sel dan granular halus dalam beberapa sel, memiliki garis batas dan beberapa bentuk poligon yang jelas. Hasil histokimia PAS (+) positif, Immunohistokimia ER (+) positif > 20-50% pada sel-sel tumor, PR (+) positif < 20%, HER2 (-) negatif. Dari hasil pemeriksaan tersebut, pasien didiagnosis Glycogen rich clear cell carcinoma. Kesimpulan: Glycogen rich clear cell carcinoma pada payudara adalah tumor yang jarang, perilaku klinisnya dilaporkan agak agresif sejauh ini, sangat bervariasi tergantung pada karakteristik khusus seperti tingkat rendah. Kata kunci: Glycogen rich clear cell carcinoma, karsinoma payudara, pewarnaan PAS.


2020 ◽  
Vol 203 ◽  
pp. e915
Author(s):  
Marina Deuker* ◽  
Franziska Stolzenbach ◽  
Giuseppe Rosiello ◽  
Angela Pecoraro ◽  
Stefano Luzzago ◽  
...  

2020 ◽  
Vol 8 (6) ◽  
pp. 632-636
Author(s):  
Karich N. ◽  
◽  
Miry A. ◽  
Tiabi M. ◽  
Aissaoui A. ◽  
...  

2013 ◽  
Vol 13 (2) ◽  
pp. 79-80
Author(s):  
Zane Simtniece ◽  
Gatis Kirsakmens ◽  
Ilze Strumfa ◽  
Andrejs Vanags ◽  
Maris Pavars ◽  
...  

Abstract Here, we report surgical treatment of a patient presenting with pancreatic metastasis (MTS) of renal clear cell carcinoma (RCC) 11 years after nephrectomy. RCC is one of few cancers that metastasise in pancreas. Jaundice, abdominal pain or gastrointestinal bleeding can develop; however, asymptomatic MTS can be discovered by follow-up after removal of the primary tumour. The patient, 67-year-old female was radiologically diagnosed with a clinically silent mass in the pancreatic body and underwent distal pancreatic resection. The postoperative period was smooth. Four months after the surgery, there were no signs of disease progression.


Sign in / Sign up

Export Citation Format

Share Document